Cempra, Inc. to Present at Jefferies 2013 Global Healthcare Conference

CHAPEL HILL, N.C., May 29, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Jefferies 2013 Global Healthcare Conference at 1 p.m. EDT, Wednesday, June 5, at the Grand Hyatt in New York. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA™ (CEM-102 or fusidic acid) for the chronic, oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.

A live webcast will be available on Cempra's website at www.cempra.com. The presentation will be archived on the company's website and available for 90 days.

About Cempra, Inc.

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases.  Cempra's two lead product candidates are currently in advanced clinical development.  Solithromycin (CEM-101) is in a Phase 3 clinical trial for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan.  TAKSTA™ (CEM-102) is Cempra's second product candidate currently in a Phase 2 clinical trial for prosthetic joint infections.  Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the results of studies of our product candidates conducted by others; the results, timing, costs and regulatory review of our studies and clinical trials; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our anticipated capital expenditures and our estimates regarding our capital requirements; our ability to obtain FDA approval of our product candidates; the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; our dependence on the success of solithromycin and Taksta; and innovation by our competitors. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.

Investor and Media Contacts:

Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226 
[email protected]

Andreas Marathovouniotis
Russo Partners LLC
(212) 845-4235
[email protected] 

SOURCE Cempra, Inc.